Skip to content

Chinese Liver Cancer Clinical Survey

Chinese Liver Cancer Clinical Survey

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03161925
Acronym
CLCS
Enrollment
5000
Registered
2017-05-22
Start date
2016-11-28
Completion date
2017-08-31
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Liver Cancer

Brief summary

In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch Chinese Liver Cancer clinical Survey project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.

Detailed description

Primary liver cancer (PLC) is one of the most common malignant tumors of digestive system and also a serious threat to the health and safety of Chinese people, and has caused serious economic burden to the country. Research purposes: To understand the clinical characteristics of patients with primary liver cancer (PLC) in China; To investigate the etiology and pathogenesis of PLC in China; To understand the current status of clinical treatment of PLC in China, and to analyze the gaps among these conditions and domestic treatment guidelines, industry consensus, the international treatment guidelines; To understand the different treatment options and its clinical outcomes, and to explore the best treatment options; To explore the best clinical pathway of PLC multidisciplinary consultation; To provide the basis for the development of clinical guidelines for PLC in China.

Interventions

None listed

Sponsors

Beijing Insight Science & Technology Co. Ltd.
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PLC after January 1,2012; * First treatment and efficacy evaluation.

Exclusion criteria

* Complicated with another primary malignant tumor and secondary liver cancer.

Design outcomes

Primary

MeasureTime frameDescription
Overall survival5 yearsOverall survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026